AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 282: H131-H137, 2002;
0363-6135/02 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (36)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brixius, K.
Right arrow Articles by Schwinger, R. H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brixius, K.
Right arrow Articles by Schwinger, R. H. G.
Vol. 282, Issue 1, H131-H137, January 2002

Beneficial effects of the Ca2+ sensitizer levosimendan in human myocardium

Klara Brixius, Sebastian Reicke, and Robert H. G. Schwinger

Laboratory of Muscle Research and Molecular Cardiology, Clinic III of Internal Medicine, University of Cologne, D-50924 Köln, Germany

Levosimendan has been reported to increase cardiac Ca2+ sensitivity, thereby not enhancing intracellular Ca2+ or diastolic tension. This may be advantageous for the treatment of heart failure patients. Therefore, the present study investigates the mode of action of levosimendan in both failing and nonfailing (NF) human myocardium. The effects of levosimendan on contractile force, Ca2+ transient (fura 2), and the force-frequency relationship (0.5-3 Hz) were studied in left ventricular terminally failing [dilated cardiomyopathy (DCM; n = 18)] and nonfailing (NF) myocardium (donor hearts, n = 6). Levosimendan (0.03-10 µmol/l) increased contractile force in NF (EC50: 0.38 µmol/l). In left ventricular failing myocardium, levosimendan only increased force after prestimulation with isoprenaline (0.1 µmol/l, EC50 levosimendan: 0.062 µmol/l) or after elevation of the extracellular Ca2+ concentration from 1.8 to 3.2 mmol/l. After application of isoprenaline, levosimendan shortened relaxation and contraction kinetics. Levosimendan did not change the systolic Ca2+ transient but it improved the force-frequency relationship in DCM. In conclusion, levosimendan improves contraction in failing human myocardium under conditions with already increased intracellular Ca2+.

heart failure; contraction; Ca2+ transient


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
P. N. Banfor, L. C. Preusser, T. J. Campbell, K. C. Marsh, J. S. Polakowski, G. A. Reinhart, B. F. Cox, and R. M. Fryer
Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H238 - H248.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
R. R. Lamberts, N. Hamdani, T. W. Soekhoe, N. M. Boontje, R. Zaremba, L. A. Walker, P. P. de Tombe, J. van der Velden, and G. J. M. Stienen
Frequency-dependent myofilament Ca2+ desensitization in failing rat myocardium
J. Physiol., July 15, 2007; 582(2): 695 - 709.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. M. Givertz, C. Andreou, C. H. Conrad, and W. S. Colucci
Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships
Circulation, March 13, 2007; 115(10): 1218 - 1224.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade
Evidence-based use of levosimendan in different clinical settings
Eur. Heart J., August 2, 2006; 27(16): 1908 - 1920.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
G. L Earl and J. T Fitzpatrick
Levosimendan: A Novel Inotropic Agent for Treatment of Acute, Decompensated Heart Failure
Ann. Pharmacother., November 1, 2005; 39(11): 1888 - 1896.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
H. Tachibana, H.-J. Cheng, T. Ukai, A. Igawa, Z.-S. Zhang, W. C. Little, and C.-P. Cheng
Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure
Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H914 - H922.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
C. W. Tong, R. D. Gaffin, D. C. Zawieja, and M. Muthuchamy
Roles of phosphorylation of myosin binding protein-C and troponin I in mouse cardiac muscle twitch dynamics
J. Physiol., August 1, 2004; 558(3): 927 - 941.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J.G.F. Cleland, A. Takala, M. Apajasalo, N. Zethraeus, and G. Kobelt
Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial
Eur J Heart Fail, January 1, 2003; 5(1): 101 - 108.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online